Peroxisome proliferator-activated receptor (PPAR)-α activation prevents diabetes in OLETF rats: Comparison with PPAR-γ activation

Diabetes

Volumn 52, Issue 9, 2003, Pages 2331-2337

  Koh, Eun Hee ^a   Kim, Min Seon ^a   Park, Joong Yeol ^a   Kim, Hyun Sik ^b   Youn, Ji Young ^b   Park, Hye Sun ^b   Youn, Jang Hyun ^c   Lee, Ki Up ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b Asan Institute for Life Sciences   (South Korea)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FENOFIBRATE; INSULIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; ROSIGLITAZONE; TRIACYLGLYCEROL;

ADIPOSE TISSUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATROPHY; BODY FAT; BODY WEIGHT; CONTROLLED STUDY; DISEASE ASSOCIATION; GLUCOSURIA; HORMONE ACTION; HYPERTROPHY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PANCREAS ISLET; PANCREAS ISLET BETA CELL; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RAT; RECEPTOR SENSITIVITY; SKELETAL MUSCLE; SOLEUS MUSCLE;

ADIPOSE TISSUE; ANIMALS; ANTILIPEMIC AGENTS; BASAL METABOLISM; BLOOD GLUCOSE; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 2; FATTY ACIDS; GLYCOGEN; HYPOGLYCEMIC AGENTS; INSULIN; ISLETS OF LANGERHANS; MALE; MUSCLE, SKELETAL; OBESITY; PROCETOFEN; RATS; RATS, INBRED OLETF; RECEPTORS, CYTOPLASMIC AND NUCLEAR; THIAZOLES; THIAZOLIDINEDIONES; TRANSCRIPTION FACTORS; TRIGLYCERIDES; VISCERA;

EID: 0042822095     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.52.9.2331     Document Type: Article

References (36)

1. Kelley DE, Goodpaster BH: Skeletal muscle triglyceride: an aspect of regional adiposity and insulin resistance. Diabetes Care 24:933-941, 2001
2. Unger RH, Zhou YT: Lipotoxicity of β-cells in obesity and in other causes of fatty acid spillover. Diabetes 50:S118-S121, 2001
3. Lowell BB: PPAR γ: an essential regulator of adipogenesis and modulator of fat cell function. Cell 99:239-242, 1999
4. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA: An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPARgamma). J Biol Chem 270:12953-12956, 1995
5. Ye JM, Doyle PJ, Iglesias MA, Watson DG, Cooney GJ, Kraegen EW: Peroxisome proliferator-activated receptor (PPAR)-α activation lowers muscle lipids and improves insulin sensitivity in high fat-fed rats: comparison with PPAR-α activation. Diabetes 50:411-417, 2001
6. Shimabukuro M, Zhou YT, Lee Y, Unger RH: Troglitazone lowers islet fat and restores beta cell function of Zucker diabetic fatty rats. J Biol Chem 273:3547-3550, 1998
7. Auboeuf D, Rieusset J, Fajas L, Vallier P, Frering V, Riou JP, Staels B, Auwerx J, Laville M, Vidal H: Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-α in humans: no alteration in adipose tissue of obese and NIDDM patients. Diabetes 46:1319-1327, 1997
8. Furnsinn C, Waldhausl W: Thiazolidinediones: metabolic actions in vitro. Diabetologia 45:1211-1223, 2002
9. Yu JG, Javorschi S, Hevener AL, Kruszynska YT, Norman RA, Sinha M, Olefsky JM: The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes 51:2698-2674, 2002
10. Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, Mori Y, Ide T, Murakami K, Tsuboyama-Kasaoka N, Ezaki O, Akanuma Y, Gavrilova O, Vinson C, Retiman ML, Kagechika H, Shudo K, Yoda M, Nakano Y, Tobe K, Nagai R, Kimura S, Tomita M, Froguel P, Kadowaki T: The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7:941-946, 2001
11. Braissant O, Foufelle F, Scotto C, Dauca M, Wahli W: Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology 137:354-366, 1996
12. Gulick T, Cresci S, Caira T, Moore DD, Kelly DP: The peroxisome proliferator-activated receptor regulates mitochondrial fatty acid oxidative enzyme gene expression. Proc Natl Acad Sci U S A 91:11012-11016, 1994
13. Muoio DM, Way JM, Tanner CJ, Winegar DA, Kliewer SA, Houmard JA, Kraus WE, Dohm GL: Peroxisome proliferator-activated receptor α regulates fatty acid utilization in primary human skeletal muscle cells. Diabetes 51:901-909, 2002
14. Guerre-Millo M, Gervois P, Raspe E, Madsen L, Poulain P, Derudas B, Herbert JM, Winegar DA, Willson TM, Fruchart JC, Berge RK, Staels B: Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity. J Biol Chem 275:16638-16642, 2000
15. Zhou YT, Shimabukuro M, Wang MY, Lee Y, Higa M, Milburn JL, Newgard CB, Unger RH: Role of peroxisome proliferator-activated receptor alpha in disease of pancreatic beta cells. Proc Natl Acad Sci U S A 95:8898-8903, 1998
16. Suzuki K, Bonner-Weir S, Hollister J, Weir GC: A method for estimating number and mass of islets transplanted within a membrane device. Cell Transplant 5:613-625, 1996
17. Ross R, Leger L, Guardo R, De Guise J, Pike BG: Adipose tissue volume measured by magnetic resonance imaging and computerized tomography in rats. J Appl Physiol 70:2164-2172, 1991
18. Kim CH, Youn JH, Park JY, Hong SK, Park KS, Park SW, Suh KI, Lee KU: Effects of high-fat diet and exercise training on intracellular glucose metabolism in rats. Am J Physiol 278:E977-E984, 2000
19. Youn JH, Kim JK, Buchanan TA: Time courses of changes in hepatic and skeletal muscle insulin action and GLUT4 protein in skeletal muscle after STZ injection. Diabetes 43:564-571, 1994
20. Kraegen EW, James DE, Jenkins AB, Chisholm DJ: Dose response curve for in vitro insulin sensitivity in individual tissues in rats. Am J Physiol 248:E353-E362, 1985
21. Chan TM, Exton JH: A rapid method for the determination of glycogen content and radioactivity in small quantities of tissue or isolated hepatocytes. Anal Biochem 71:96-105, 1976
22. Lee Y, Hirose H, Zhou YT, Esser V, McGarry JD, Unger RH: Increased lipogenic capacity of the islets of obese rats. Diabetes 46:408-413, 1997
23. Gotoh M, Maki T, Satomi S, Porter J, Bonner-Weir S, O'Hara CJ, Monaco AP: Reproducible high yield of rat islets by stationary in vitro digestion following pancreatic ductal or portal venous collagenase injection. Transplantation 43:725-730, 1987
24. Briaud I, Harmon JS, Kelpe CL, Segu VB, Poitout V: Lipotoxicity of the pancreatic beta-cell is associated with glucose-dependent esterification of fatty acids into neutral lipids. Diabetes 50:315-321, 2001
25. Oakes ND, Camilleri S, Furler SM, Chisholm DJ, Kraegen EW: The insulin sensitizer, BRL 49653, reduces systemic fatty acid supply and utilization and tissue lipid availability in the rat. Metabolism 46:935-942, 1997
26. Fonseca VA, Valiquett TR, Huang SM, Ghazzi MN, Whitcomb RW: Troglitazone monotherapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled study: the Troglitazone Study Group. J Clin Endocrinol Metab 83:3169-3176, 1998
27. Oakes ND, Thalen PG, Jacinto SM, Ljung B: Thiazolidinediones increase plasma-adipose tissue FFA exchange capacity and enhance insulin-mediated control of systemic FFA availability. Diabetes 50:1158-1165, 2001
28. Cha BS, Ciaraldi TP, Carter L: Peroxisome proliferator-activated receptor (PPAR) gamma and retinoid X receptor (RXR) agonists have complementary effects on glucose and lipid metabolism in human skeletal muscle. Diabetologia 44:444-452, 2001
29. Piro S, Anello M, Di Pietro C, Lizzio MN, Patane G, Rabuazzo AM, Vigneri R, Purrello M, Purrello F: Chronic exposure to free fatty acids or high glucose induces apoptosis in rat pancreatic islets: possible role of oxidative stress. Metabolism 51:1340-1347, 2002
30. Steil GM, Trivedi N, Jonas JC, Hasenkamp WM, Sharma A, Bonner-Weir S, Weir GC: Adaptation of beta cell mass to substrate oversupply: enhanced function with normal gene expression. Am J Physiol 280:E788-E796, 2001
31. Man ZW, Zhu M, Noma Y, Toide K, Sato T, Asahi Y, Hirashima T, Mori S, Kawano K, Mizuno A, Sano T, Shima K: Impaired β-cell function and deposition of fat droplets in the pancreas as a consequence of hypertriglyceridemia in OLETF rat, a model of spontaneous NIDDM. Diabetes 46:1718-1724, 1997
32. Knopp RH: Drug treatment of lipid disorders. N Engl J Med 341:498-511, 1999
33. Lawrence JW, Li Y, Chen S, DeLuca JG: Differential gene regulation in human versus rodent hepatocytes by peroxisome proliferator-activated receptor (PPAR) alpha: PPAR alpha fails to induce peroxisome proliferation-associated genes in human cells independently of the level of receptor expression. J Biol Chem 276:31521-31527, 2001
34. Cattley RC, DeLuca J, Elcombe C, Fenner-Crisp P, Lake BG, Marsman DS, Pastoor TA, Popp JA, Robinson DE, Schwetz B, Tugwood J, Wahli W: Do peroxisome proliferating compounds pose a hepatocarcinogenic hazard to humans? Regul Toxicol Pharmacol 27:47-60, 1998
35. Sane T, Knudsen P, Vuorinen-Markkola H, Yki-Jarvinen H, Taskinen MR: Decreasing triglyceride by gemfibrozil therapy does not affect the glucoregulatory or antilipolytic effect of insulin in nondiabetic subjects with mild hypertriglyceridemia. Metabolism 44:589-596, 1995
36. Asplund-Carlson A: Effects of gemfibrozil therapy on glucose tolerance, insulin sensitivity and plasma plasminogen activator inhibitor activity in hypertriglyceridaemia. J Cardiovasc Risk 3:385-390, 1996